MBX Biosciences, Inc.
MBXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MBX. That does not mean none is planned.
Get an email about MBX's next catalysts
Track MBX Biosciences (MBX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
MBX 2109
Hypoparathyroidism
MBX 2109 - by subcutaneous
Hypoparathyroidism
MBX 1416 (INN imapextide)
Postbariatric Hypoglycemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MBX 2109 | Phase 2 | Hypoparathyroidism | - | - |
MBX 2109 - by subcutaneous | Phase 2 | Hypoparathyroidism | - | - |
MBX 1416 (INN imapextide) | Phase 2 | Postbariatric Hypoglycemia | - | - |
Frequently asked questions
What is in MBX Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in MBX Biosciences, Inc.'s (MBX) pipeline across Phase 2. Its lead program is MBX 1416 (INN imapextide) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MBX Biosciences, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for MBX Biosciences, Inc. (MBX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MBX biotech catalysts?→
Add MBX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MBX Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.